TPST

TPST

USD

Tempest Therapeutics Inc. Common Stock

$6.990-0.035 (-0.498%)

Цена в режиме реального времени

Healthcare
Биотехнология
Соединенные Штаты

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$7.025

Максимум

$7.230

Минимум

$6.650

Объем

0.01M

Фундаментальные показатели компании

Рыночная капитализация

24.6M

Отрасль

Биотехнология

Страна

United States

Статистические данные торговли

Средний объем

0.06M

Биржа

NCM

Валюта

USD

52-недельный диапазон

Минимум $5.356Текущая $6.990Максимум $49.27

Связанные новости

GlobeNewswire

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight

Просмотреть больше
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
GlobeNewswire

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight

Просмотреть больше
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
Analyst Upgrades

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.

Просмотреть больше
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Analyst Upgrades

Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Lowers Price Target to $9

Scotiabank analyst George Farmer downgrades Tempest Therapeutics from Sector Outperform to Sector Perform and lowers the price target from $91 to $9.

Просмотреть больше
Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Lowers Price Target to $9
Analyst Upgrades

HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16

HC Wainwright & Co. analyst Joseph Pantginis downgrades Tempest Therapeutics from Buy to Neutral and maintains the price target from $16 to $16.

Просмотреть больше
HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16
GlobeNewswire

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug & Fast Track

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.